Revelation Biosciences, Inc..
REVB.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics and diagnostics in the fields of infectious disease, inflammation, and allergy. The company's lead product candidate is REVTx-99, an intranasal immunomodu...Show More
Better Health for All
10
Revelation Biosciences is a clinical-stage biopharmaceutical company entirely focused on developing therapeutics and diagnostics for significant health issues, including acute and chronic kidney disease, post-surgical and burn infections, and respiratory viral infections.
1
Its lead product candidate, Gemini, and REVTx-99 have shown strong safety and tolerability in Phase 1 studies, with most adverse events being mild and only three severe events (chills, nausea, vomiting) reported at the highest dose, resolving within 3 hours, with no serious adverse events.
2
The company's diagnostic product, REVDx-501, is designed as a rapid, self-contained, and portable point-of-care test, providing results in less than 10 minutes without specialized instrumentation.
3
Revelation Biosciences is developing therapies for conditions that affect vulnerable populations such as the critically ill, burn-injured, elderly, immune-suppressed, and those with acute or chronic kidney disease.
4
However, there is no evidence regarding the actual reach or access for low-income or marginalized populations. The company's press releases contain forward-looking statements and caution investors about risks and uncertainties, indicating a moderate level of risk transparency.
5
Clinical trials for Gemini and REVTx-99 have enrolled 40 healthy individuals and 40 CKD patients, respectively, across US and Australian clinics, meeting primary safety endpoints and reporting results, demonstrating strong ethical conduct.
6
The company's products, such as REVTx-99, are explicitly developed for the prevention of respiratory viral infections, and Gemini is being developed as a single-dose preconditioning therapy.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Revelation Biosciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The company's employee work satisfaction rating is 3.3/5, which translates to 66/100.
1
This falls between the rubric's -10 tier (65/100) and 10 tier (70/100). Following the rule to choose the tier closer to zero, the score maps to -10. No specific, concrete data points were found for living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Revelation Biosciences, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete data points relevant to the 'Honest & Fair Business' ethical value or its associated KPIs were found in the provided articles. The articles either indicated content was unavailable or explicitly stated no relevant data was present for the company or the requested metrics.
1
Kind to Animals
0
No relevant data was found in the provided articles to assess Revelation Biosciences, Inc. against the 'Kind to Animals' ethical value. All articles indicated a 404 error or 'page not found', meaning no specific facts, figures, or policies regarding animal welfare, testing, sourcing, or conservation could be extracted.
1
No War, No Weapons
0
No evidence available to assess Revelation Biosciences, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific data regarding Revelation Biosciences, Inc.'s internal environmental performance or sustainability initiatives, such as greenhouse gas emissions, renewable energy usage, water consumption, waste diversion rates, climate targets, or environmental compliance, is available in the provided articles.
1
The articles either focus on general industry trends, corporate financial events, or explicitly state that sustainability data for the company is not available.
Respect for Cultures & Communities
0
No evidence was found in the provided articles regarding Revelation Biosciences, Inc.'s performance or activities related to Respect for Cultures & Communities. The articles focus on clinical trial approvals, financial events, and corporate announcements, without addressing community engagement, cultural impact, or related initiatives.
Safe & Smart Tech
0
Insufficient evidence is available to assess Revelation Biosciences' performance regarding Safe & Smart Tech. The provided articles do not contain relevant information about the company's data protection, cybersecurity practices, AI ethics governance, or other related metrics.
1
,
2
The company's business model as a clinical-stage biopharmaceutical company has a low level of materiality to this value, primarily relating to data security in clinical trials. Without specific data on their security measures, training, or compliance, a neutral score is assigned. The materiality analysis indicates that scores above 5 should be flagged as illogical.
Zero Waste & Sustainable Products
0
No sustainability data, including information related to waste diversion, product recyclability, packaging sustainability, or any other zero-waste initiatives, is available for Revelation Biosciences, Inc. in the provided articles.
1
Therefore, no KPIs under the 'Zero Waste & Sustainable Products' value can be scored.